United States - English - NLM (National Library of Medicine)

medsource pharmaceuticals - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 50 mg - losartan potassium tablets, usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents, including diuretics. losartan potassium tablets, usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients (see precautions, race and clinical pharmacology, pharmacodynamics and clinical effects, reduction in the risk of stroke , race ). losartan potassium tablets, usp are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥ 300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creat

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

United States - English - NLM (National Library of Medicine)

granules india ltd - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release capsules are indicated for the treatment and prophylaxis of hypokalemia in adults and children with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride extended-release capsules are contraindicated in patients on amiloride or triamterene. risk summary there are no human data related to use of potassium chloride extended-release capsules during pregnancy and animal reproductive studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. r

Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - sodium chloride ; calcium chloride dihydrate ; potassium chloride ; sodium lactate solution 60% - solution for infusion - 6/0.27/0.4 grams - electrolytes

Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - sodium chloride ; calcium chloride dihydrate ; potassium chloride ; sodium lactate solution 60% - solution for infusion - grams - electrolytes

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

maco pharma (uk - sodium chloride; potassium chloride; calcium chloride; sodium lactate - infusion - 6mg/1ml ; 400microgram/1ml ; 270microgram/1ml ; 3.17mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

maco pharma (uk - sodium chloride; potassium chloride; calcium chloride; sodium lactate - infusion - 6mg/1ml ; 400microgram/1ml ; 270microgram/1ml ; 3.17mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma - sodium chloride - solution for infusion - 0.9 percent weight/volume - solutions affecting the electrolyte balance; electrolytes

Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma - glucose monohydrate - solution for infusion - 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates